Akoya Biosciences, Inc. (AKYA) [Rocket]

Date Filed

Type

Description

08/07/2023

8-K

Quarterly results

07/13/2023

144

Form 144 - Report of proposed sale of securities:

07/12/2023

144

Form 144 - Report of proposed sale of securities:

07/05/2023

8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

06/28/2023

8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

06/13/2023

SC 13G

Schindel Yair Chaim reports a 6% stake in Akoya Biosciences, Inc.

06/12/2023

4

Ek John Frederick (CFO) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 20,000 shares @ $5, valued at $100k

06/12/2023

4

LAI GOLDMAN MYLA (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 20,000 shares @ $5, valued at $100k

06/12/2023

4

Mendel Scott (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 20,000 shares @ $5, valued at $100k

06/12/2023

4

Winkler Matthew (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 203,388 shares @ $5, valued at $1M

06/12/2023

4

SHEPLER ROBERT G (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 120,000 shares @ $5, valued at $600k

06/12/2023

4

Raffin Thomas A. (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Bought 20,000 shares @ $5, valued at $100k
Bought 196,627 shares @ $5, valued at $983.1k
Bought 1,803,373 shares @ $5, valued at $9M

06/12/2023

8-K

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data

Docs:

"Akoya Biosciences, Inc. 8,700,000 Shares of Common Stock Underwriting Agreement",
"DLA Piper LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 T 677-1400 F 677-1401 W www.dlapiper.com",
"AKOYA BIOSCIENCES ANNOUNCES PUBLIC OFFERING OF COMMON STOCK",
"AKOYA BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK"

06/09/2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]:

06/07/2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]:

06/07/2023

8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

Docs:

"2 Akoya Disclaimer Disclaimer Akoya Biosciences, Inc. has filed a registration statement with the Securities Exchange Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, including the preliminary prospectus supplement, and other documents the Company has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone at 1-866-718-1649 or by ..."

06/06/2023

4

McKelligon Brian (President/CEO) has filed a Form 4 on Akoya Biosciences, Inc.

Txns:

Sold 5,000 shares @ $5.7074, valued at $28.5k
Exercised 5,000 options to buy @ $0.303, valued at $1.5k

06/06/2023

144

Form 144 - Report of proposed sale of securities:

06/06/2023

144

Form 144 - Report of proposed sale of securities:

06/05/2023

4

Winkler Matthew (Director) has filed a Form 4 on Akoya Biosciences, Inc.

Txns: